# Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

> **NCT06947291** · PHASE2 · RECRUITING · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 350 (estimated)

## Conditions studied

- Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

## Interventions

- **DRUG:** Glumetinib Tablets
- **DRUG:** Docetaxel for Injection (Albumin-bound)

## Key facts

- **NCT ID:** NCT06947291
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06947291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06947291, "Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06947291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*